ElevateBio Capacity Update July 2024: Cell & Gene Therapy

Lentiviral vectors (LVVs) are a cornerstone in the advancing field of cell and gene therapy, enabling precise delivery of genetic material for treatments such as CAR-T and HSC-based therapies. However, the rising demand for LVVs in clinical applications has exposed significant challenges, including high costs, lengthy manufacturing timelines, and regulatory concerns with traditional production methods.

ElevateBio BaseCamp’s LentiPeak™ LVV Production Platform offers a robust, scalable, and cost-effective solution to these challenges. Designed for transient transfection of serum-free, suspension-grown cells, LentiPeak™ produces high-quality LVVs tailored for a variety of therapeutic applications, including CAR/TCR constructs. The platform delivers impressive upstream infectious titers (~1E8 TU/mL) with low particle-to-infectious titer ratios (< 1000 particles/TU) across a range of transgenes. It ensures scalability in both small- and large-scale bioreactors and employs single-use technologies and non-animal-derived raw materials throughout the process for enhanced reliability and compliance.

BaseCamp streamlines workflows for partners by aligning equipment, protocols, and data collection tools, facilitating a seamless transition from process development to GMP manufacturing. The final LVV product achieves efficient transduction of primary cells with significantly reduced host cell protein (HCP), host cell DNA, and plasmid DNA impurities. Furthermore, BaseCamp’s LentiPeak™ platform offers immediate manufacturing slot availability and research-grade production to rapidly onboard new partners and advance therapeutic development timelines.